Clinical trials: Circulating Tumor DNA
Colorectal Cancer
Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance
This study is designed to prospectively collect blood samples and clinical data from patients that have been newly diagnosed with colorectal cancer and scheduled for resection surgery but are pre cancer treatment, subjects who…
- Trial name
- PROVE (NCT07310446)
- Where
- United States
- Volunteers
- 6,500 people, healthy volunteers welcome
- Sponsor
- Universal Diagnostics
Non-Clear Cell Renal Cell Carcinoma
Personalized ctDNA Monitoring for Predicting Immunotherapy Outcomes in Advanced Non-Clear Cell Renal Cell Carcinoma
This is a prospective, non-interventional observational cohort study evaluating the clinical utility of patient-specific circulating tumor DNA (ctDNA) monitoring in patients with advanced non-clear cell renal cell carcinoma…
- Trial name
- NCT07776483
- Testing
- Patient-Specific Tumor-Informed ctDNA Monitoring
- Volunteers
- 67 people
- Sponsor
- West China Hospital
Mutation, Neoplasms
Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease
Pathway Genomics Corporation (Pathway Genomics), a San Diego, California company, is involved in the development and validation of new molecular diagnostic assays for the analysis of circulating tumor deoxyribonucleic acid (DNA)…
- Trial name
- H1000 (NCT02612350)
- Testing
- ctDNA Analysis for the Detection of Genetic Mutations
- Where
- United States
- Volunteers
- 1,106 people, healthy volunteers welcome
- Sponsor
- Pathway Genomics
Breast Cancer, Neoadjuvant Chemotherapy
Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Breast cancer is the most common malignant tumor in women worldwide,and there exist a large part of patients need to receive neoadjuvant chemotherapy(NAC) before the curative surgery.Circulating tumor DNA(ctDNA) is the…
- Conditions
- Breast Cancer, Neoadjuvant Chemotherapy, Circulating Tumor DNA
- Trial name
- NCT03688035
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zhiyong Yu
Non-Small Cell Lung Cancer, Adjuvant Therapy
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
This multicenter, randomized, open-label, phase II trial is designed to evaluate the efficacy and safety of adjuvant sintilimab in patients with completely resected non-small cell lung cancer who remain at high risk of recurrence…
- Conditions
- Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- RICA (NCT07748325)
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sichuan University
Primary Mediastinal Large B-cell Lymphoma
Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)
The purpose of this study is to compare the predictive value in terms of specificity of circulating tumor DNA (ctDNA) and positron emission computed tomography (PET-CT) after 2 cycles of chemotherapy (C2), on the probability of…
- Trial name
- CAMIL (NCT04824950)
- Testing
- Circulating tumor DNA monitoring
- Where
- 2 sites in France
- Volunteers
- 87 people
- Sponsor
- Centre Henri Becquerel
Locally Advanced Head and Neck Carcinoma
cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.
- Trial name
- NeckTAR-IN (NCT07178847)
- Testing
- blood sampling
- Where
- 4 sites in France
- Volunteers
- 59 people
- Sponsor
- Centre Jean Perrin
Immunotherapy, Cervical Cancer
Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions
Immunotherapy is the main option for advanced, recurrent and metastatic cervical cancer. However, due to the complex interaction between the immune system and tumors, there is still a lack of effective markers for immunotherapy.
- Conditions
- Immunotherapy, Cervical Cancer, CtDNA, Biomarker
- Trial name
- NCT06649838
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Non-Small Cell Lung Cancer
Liquid Biopsy Genotyping Using Oncomine Precision Assay GX in Advanced NSCLC
This interventional clinical study evaluates the clinical utility and feasibility of the Oncomine Precision Assay GX method for genotyping circulating tumor DNA (ctDNA) in patients with advanced non-small cell lung cancer…
- Trial name
- Liquid biopsy (NCT07432308)
- Testing
- Oncomine Precision Assay GX ctDNA Testing
- Where
- Slovenia
- Volunteers
- 22 people
- Sponsor
- Institute of Oncology Ljubljana
Gastric Cancer
Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic Gastric Cancer
To evaluate the clinical significance of cell free DNA (cfDNA) and circulating tumor cells (CTCs) in real-time monitoring the therapeutic response during HER2-targeted therapy in histologically confirmed HER2 positive…
- Trial name
- NCT02610218
- Testing
- CTC and cfDNA analysis
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Peking University
Circulating Tumor Cells, Pancreatic Adenocarcinoma
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
Histological proof is a crucial and necessary step for appropriate care in oncology. In the case of pancreatic cancer, histological proof from pathological analysis of the surgical specimen is very rare due to the limited number…
- Conditions
- Circulating Tumor Cells, Pancreatic Adenocarcinoma, Circulating Tumor DNA (KRAS), CA 19.9
- Trial name
- CTC-Pancreas (NCT02072616)
- Testing
- Pancreatic adenocarcinoma diagnosis
- Where
- France
- Volunteers
- 101 people
- Sponsor
- University Hospital, Rouen
Pancreatic Ductal Adenocarcinoma (PDAC), NGS Monitor MRD
ctDNA Monitoring After Pancreatic Cancer Surgery (K-4CARE Lite Study)
Pancreatic ductal adenocarcinoma (PDAC) carries one of the worst prognoses among solid tumors. Even after curative-intent resection, 70-80% of patients recur within two years.
- Trial name
- K4CARE-PDAC (NCT07597252)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Chang Gung Memorial Hospital
Non Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
SCION: SABR and Checkpoint Inhibition of NSCLC
The SCION Trial is a clinical trial in patients with early stage non-small cell lung cancer. The purpose of the trial is to investigate whether it is safe and effective to combine standard radiation treatment with a drug called…
- Conditions
- Non Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Non-small Cell Lung Cancer Stage I, Lung Cancer
- Trial name
- SCION (NCT04944173)
- Testing
- Durvalumab, Stereotactic Body Radiotherapy, Circulating Tumor DNA assay
- Where
- 5 sites in Canada
- Sponsor
- University of British Columbia
Colorectal Cancer Metastatic, Advanced Non-Small Cell Lung Carcinoma
The Oncopanel Pilot (TOP) Study
The BCCA Oncopanel is a clinical assay being developed to determine genotype status of a prospectively defined set of genes. The purpose of this pilot study is to assess the feasibility and effect on clinical-decision-making of…
- Conditions
- Colorectal Cancer Metastatic, Advanced Non-Small Cell Lung Carcinoma, Advanced Melanoma, Gastrointestinal Stromal Tumors
- Trial name
- NCT02171286
- Where
- 5 sites in Canada
- Volunteers
- 432 people
- Sponsor
- British Columbia Cancer Agency
Colorectal Cancer Screening
Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas
The purpose of this study is to collect clinical specimens from subjects with a diagnosis of colorectal cancer/advanced adenoma or undergoing a screening colonoscopy and meeting study eligibility criteria.
- Trial name
- NCT05127096
- Testing
- FirstSight blood test
- Where
- 15 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- CellMax Life
High Grade Glioma
Circulating Tumor DNA Collection From Patients With High Grade Gliomas
Improved outcomes for high-grade gliomas (HGG) require advances in our ability to monitor changes to tumour biology using non-surgical approaches.
- Trial name
- m-ctDNA (NCT05925218)
- Testing
- Radiotherapy as per standard of care
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- University Health Network, Toronto
Head and Neck Cancer, Advanced Cancer
Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)
This study aims to study the kinetics of ctDNA levels after the first dose of immune checkpoint inhibitor in patients with recurrent or metastatic head and neck cancer.
- Conditions
- Head and Neck Cancer, Advanced Cancer, Metastatic Cancer, HNSCC
- Trial name
- NCT04606940
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- University Health Network, Toronto
Melanoma
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
There is evidence from cohort studies and metanalysis that a shift from BRAFWT to BRAF mutated melanomas can occur (Colombino JCO 2012, Valchis EJC 2017).
- Trial name
- NCT05299580
- Testing
- dabrafenib, Trametinib
- Where
- 16 sites in Italy
- Sponsor
- Fondazione Melanoma Onlus
Metastatic Colorectal Cancer, Circulating Tumor DNA
ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases
This is a prospective multicenter cohort study, was designed to explore the prognostic value of ctDNA as a biomarker of disease response and recurrence or death in patients undergoing curative-intent surgical resection of…
- Trial name
- CLIMES (NCT05787197)
- Where
- 16 sites in France
- Volunteers
- 232 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Prostate Cancer
Circulating Tumor DNA in High Risk Localized Prostate Cancer
This prospective, non-therapeutic translational biomarker study will collect blood in patients with high risk localized prostate cancer prior to prostatectomy.
- Trial name
- NCT07222436
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Pittsburgh